Evaluation of The Relationship Between Apelin 36 and Oxidative Stress In Patients With General Anxiety Disorder

Year 2021, Volume: 7 Issue: 3, 397 - 403, 31.12.2021

İlkay Bahçeci Umut Serkan Söztanacı Meltem Puşuroğlu Nuray Arslan Ömer Faruk Duran Bulent Bahceci Zihni Acar Yazıcı

https://doi.org/10.19127/mbsjohs.1024605

Cited By: 1

Abstract

Objective: The aim of this study was to evaluate the relationship between apelin-36 and oxidative parameters and Generalized Anxiety Disorder (GAD). Apelin which prevents hippocampal neuronal death is an endogenous ligand for G protein bound APJ receptors in the central nervous system. Oxidative Stress were occurred by free radicals which caused apoptosis in the hypothlamus, hippocampus and amygdala regions of the Central Nervous System (CNS).
Methods: In this study, 61 patients diagnosed generalized anxiety disorder at psychiatry polyclinic and 55 control subjects were enrolled. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and the Hamilton Anxiety Rating Scale (HARS) were used in this study and they were filled by the patients and healthy individuals. Serum apelin-36 level was measured by using an ELISA kit. Total antioxidant status (TAS) and Total Oxidant Status (TOS) in the serum was measured by an automated system. The data were analyzed by using the SPSS.
Results: It was found that serum apelin-36, TOS and Oxidative stress index (OSI) levels were significantly lower in patients’ group than controls. In addition, negative correlation was detected between apelin 36 levels and HARS scores, TOS and OSI values in patients’ group. TAS values were found as similar between the patient and control group. There was no correlation between TAS and Apelin 36 in the patient group.
Conclusion: In this study it was found that serum apelin-36, TOS and OSI levels were low in GAD. According to the results, Apelin-36 and oxidative stress may play a role in the etiopathogenesis of Generalized Anxiety Disorder.

Keywords

Apelin 36, , General Anxiety Disorder,, Oxidative stress,, Total antioxidant status,, total oxidant status

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Stein MB. Public Health Perspectives on Generalized Anxiety Disorders. J Clin Psychiatry 2004;65: 3–7.
• 2. Pitsavos C, Panagiotakos D, Papageorgiou C, Tsetsekou E, Soldatos C, Stefanadis C. Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis 2006;185(2):320–6.
• 3. Ding L, Zhang C, Masood A, Jianxin Li, Jiao Sun et al. Protective effects of phosphodiesterase 2 inhibitor on depression and anxiety like behaviors: Involvement of antioxidant and anti-apoptotic mechanisms. Behav Brain Res 2014;268:150–8.
• 4. Mcgaugh J, Mclntyre C, Power A. Amygdala modulation of memory consolidation: İnteraction with other brain systems. Neurobiol Learn Mem 2002;78(3):539–52.
• 5. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophsy Res Commun1998;251(2):471–6. 6. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y et al. Molecular and functional characteristics of APJ: Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000;275(28):21061–21067.
• 7. Sakamoto K, Murakami Y, Sawada S, Ushikubo H, Mori A et al. Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice. Eur J Pharmacol 2016;791:213–220.
• 8. O’Donnell LA, Agrawal A, Sabnekar P, Dichter MA, Lynch KD. Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury. J Neurochem 2007;102(6):1905–1917.
• 9. Japp AG, Cruden NL, Amer DAB, Vivienne KY Li, Goudie EB et al. Vascular Effects of Apelin In Vivo in Man. J Am Coll Cardiol 2008;52(11):908–913.
• 10. Gu Q, Zhai L, Feng X, Chen J, Miao Z et al. Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int 2013;63: 535–40.
• 11. Kutlay O. The impact of apelin-36 on isolated rat hearts as a member of apelin family Bratisl Med J 2018; 119(10): 625–9.
• 12. Duman H, Bahceci İ, Hamur H, Demirelli S, Dilek AR et al. The Relationship between Serum Apelin Level s and the Severity of Calcific Aortic Stenosis. Acta Cardiol Sin 2018; 34 (3): 259–66.
• 13. Bilgiç A, Toker A, Uysal S. Exploratory study to evaluate plasma vasopressin and apelin-13 levels in children with attention-deficit hyperactivity disorder. Psychiatry Clin Neurosci 2016;70(10):442–7.
• 14. Boso M, Emanuele E, Politi P, Pace A, Arra M et al. Reduced Plasma Apelin Levels in Patients with Autistic Spectrum Disorder. Arch Med Res 2007;38(1):70–4.
• 15. Li E, Deng H, Wang B, Fu W, You Y, Tian S. Apelin-13 exerts antidepressant-like and recognition memory improving activities in stressed rats. Eur neuropsychopharmacol  2016;26(3):420–30.
• 16. Lv Sy, Qin YJ, Wang HT, Xu N, Yang YJ Chen Q. Centrally administered apelin-13 induces depression-like behavior in mice. Brain Res Bull 2012;88(6):574–80.
• 17. Telegdy G, Adamik A, Jászberényi M. Involvement of neurotransmitters in the action of apelin-13 on passive avoidance learning in mice. Peptides 2013;39(1):171–174. 18. Xin Q, Cheng B, Pan Y, Liu Haiging, Yang Chunging et al. Neuroprotective effects of apelin-13 on experimental ischemic stroke through suppression of inflammation. Peptides 2015;63:55–62.
• 19. Kokacya MH, Bahceci B, Bahceci I, Dilek AR, Dokuyucu R. Prolidase activity and oxidative stress in patients with major depressive disorder. Psychiatr Danub 2014;26:314–8.
• 20. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38 (12): 1103–1111.
• 21. First MB, Spitzer RL, Gibbon M WJ. Structured Clinical Interview for DSM-IV Clinical Version (SCID-I/CV). Washington DC: American Psychiatric Press, 1997: 25-35.
• 22. Corapcioglu A, Aydemir Ö, Yıldız M, Esen Danaci A, Koroglu E. DSM-IV Eksen-I Structured Clinical Interview for Disorders. Ankara: Physicians Publishing Union,1999: 1–7.
• 23. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–5.
• 24. Yazici MK, Demir B, Tanriverdi N, Karaagaoglu E, Yolac P. Hamilton Anxiety Rating Scale: Interrater reliability and validity study January 1998. Turk Psikiyatri Derg 1998;9:114–7.
• 25. Ercan AC, Bahceci B, Polat S, Cenker OC, Bahceci I et al. Oxidative status and prolidase activities in generalized anxiety disorder. Asian J Psychiatr. 2017;25: 118-22.
• 26. Bahceci B, Bagcioglu E, Kokacya MH, Dilek AR, Bahceci I, Selek S. Prolidase activity and oxidative stress in patients with schizophrenia: A preliminary study. J Pak Med Assoc 2015;65(2): 131–35.
• 27. Bahceci B, Kokacya MH, Copoglu US, Copoglu S, Bahceci I et al. Elevated nucleosome level and oxidative stress in schizophrenia patients. Bratisl Med J 2015;116(10): 587-90.
• 28. Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In vivo 2004; 18: 377–90.
• 29. Bulut M, Selek S, Gergerlioglu HS, Savas HA, Yilmaz HR et al. Malondialdehyde levels in adult attention-deficit hyperactivity disorder. J Psychiatry Neurosci 2007; 32 (6): 435–438.
• 30. Ozdemir E, Cetinkaya S, Ersan S, Kucukosman S, Ersan EE. Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder. Prog Neuropsycho pharmacol Biol Psychiatry 2009; 33: 62–5.
• 31. Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979; 103: 359–62.
• 32. Britt SG, Chiu VW, Redpath G, Vandenberg SR. Elimination of ascorbic acid-induced membrane lipid peroxidation and serotonin receptor loss by Trolox-C, a water-soluble analogue of vitamin E. J Recept Res 1992; 12: 181–200.
• 33. Nikolaus S, Antke C, Beu M, Müller HW. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders results from in vivo imaging studies. Rev Neurosci2010; 21 (2): 119–39.
• 34. Emhan A, Selek S, Bayazit H, Karababac IF, Katic M, Aksoy N. Evaluation of oxidative and antioxidative parameters in generalized anxiety disorder. Psychiatry Res 2015; 230: 806–810.